All In Biotech

Drug Trial Radar · NCT01726452

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC or FLOT Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction

Last checked: Nov 20, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

377

Actual

Start

Jan 24, 2013

Primary completion

Aug 4, 2022

Study completion Aug 4, 2022

Sponsor

Lead sponsor
Cancer Trials IrelandResearch network
Sponsor type
Research network
Collaborators
Southampton Clinical Trials Unit; Copenhagen University Hospital, Rigshospitalet; Centre Hospitalier Régional, Universitaire de Lille
First posted
Nov 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre phase III open-labelled, randomised controlled trial. Eligible patients will be randomised in a 1:1 fashion between neoadjuvant and adjuvant chemotherapy (Investigator's choice modified MAGIC (ECF/ECX or EOF/EOX) or FLOT regimen) and surgery or Arm B (CROSS protocol: chemotherapy with radiation therapy and surgery as per multimodal protocol). Primary Objective: To evaluate one, two and three year survival of patients treated with resection plus neoadjuvant and adjuvant chemotherapy versus resection plus neoadjuvant chemo radiotherapy. Secondary Objective(s): To evaluate the effect of both neoadjuvant regimens on clinical and pathological response rate (in particular relief of dysphagia, improvement in health related quality of life (HRQL), endoscopic regression, and CT-PET evidence of tumour response), tumour regression grade, node-positivity, post-operative pathology, disease-free survival, time to treatment failure, toxicity, post-operative complications and Health Related Quality of Life (HRQL). Exploratory Objective(s): Translational Research: The collection of blood and tissue samples for storage in the bio bank for future research.

Conditions

  • Adenocarcinoma of the Oesophagus
  • Adenocarcinoma of the Oesophago-gastric Junction
  • Oesophageal Tumours
  • Junctional Tumours
  • Oesophageal Cancer

Interventions

  • EpirubicinDrug

    50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)

  • Cisplatin / OxaliplatinDrug

    Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.

  • 5 Flourouracil/ CapecitabineDrug

    5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.

  • (41.4 Gy/23 fractions)Radiation

    Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).

  • PaclitaxelDrug

    50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.

  • CarboplatinDrug

    Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29

  • DocetaxelDrug

    Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)

  • OxaliplatinDrug

    85 mg/m², day 1 of each cycle (i.e. every 14 days)

  • LeucovorinDrug

    200 mg/m², day 1 of each cycle (i.e. every 14 days).

  • 5-FluorouracilDrug

    2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: At end of trial- up to 3 years in follow up

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Blegdamsvej 9, Denmark

  • Centre Hospitalier Régional, Universitaire de Lille 2 Avenue Oscar Lambret, 59000

    Lille, France

  • Cork University Hospital

    Cork, Ireland

  • Beaumont Hospital

    Dublin, Ireland

  • SLRON- St Luke's Radiation Oncology Network

    Dublin, Ireland

  • St. James's Hospital

    Dublin, Ireland

  • University Hospital Galway

    Galway, Ireland

  • Karolinska Institutet and Karolinska University Hospital

    Stockholm, Sweden

  • Belfast Health and Social Care Trust, Northern Ireland Cancer Centre, Belfast CityHospital

    Belfast, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Birkenhead, Wirral, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom

  • University Hospital Plymouth NHS Trust

    Derriford Hospital, Derriford Road, Crownhill, Plymouth, United Kingdom

  • NHS Lothian, Edinburgh Cancer Centre,

    Edinburgh, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, 1056 Great Western Road, United Kingdom

  • Imperial College Healthcare NHS Trust St Mary's Hospital

    London, United Kingdom

  • The Newcastle upon Tyne Hospital NHS Foundation TrustFreeman Hospital, Freeman Road, High Heaton

    Newcastle upon Tyne, United Kingdom

  • Royal Preston Hospital

    Sharoe Garoo Lane, Fulwood, Preston, United Kingdom

  • The Royal Bournemouth Hospital

    The Royal Bournemouth and Christchurch Hospitals NHS Foundation, Bournemouth, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust

    Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp, Cambridge, United Kingdom

  • Velindre Cancer Centre

    Velindre NHS Trust, Velindre Road, Whitchurch, Cardiff, United Kingdom

  • University Hospitals Coventry & Warwickshire

    Clifford Bridge Road, Walsgrave, Coventry, United Kingdom

  • Hull and East Yorkshire Hospitals NHS Trust, Castle Hill Hospital,

    Cottingham, East Riding Of Yorkshire, United Kingdom

  • Portsmouth Hospitals NHS Trust

    Southwick Hill Road, Cosham, Hampshire, United Kingdom

  • Mount Vernon Cancer Centre

    E & N Hertfordshire NHS Trust, Rickmansworth Road, Northwood, Middlesex, United Kingdom

  • Nottingham City Hospital

    Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, United Kingdom

  • Oxford University Hospital NHS Trust Churchill Hospital

    Headington, Oxfordshire, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton General Hospital, Division A Cancer Care, Mp307, T, Southampton, United Kingdom

  • Royal Surrey County Hospital

    Guildford, Surrey, United Kingdom

  • Worcestershire Royal Hospital

    Worcestershire Oncology Centre, Charles Hastings Way, Worcester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.